

Article

Heart rate variability: Measurement and emerging use in critical care medicine

Johnston, Brian W, Barrett-Jolley, Richard, Krige, Anton and Welters, Ingeborg D

Available at <http://clock.uclan.ac.uk/28928/>

Johnston, Brian W, Barrett-Jolley, Richard, Krige, Anton and Welters, Ingeborg D (2019) Heart rate variability: Measurement and emerging use in critical care medicine. Journal of the Intensive Care Society . ISSN 1751-1437

It is advisable to refer to the publisher's version if you intend to cite from the work.

<http://dx.doi.org/10.1177/1751143719853744>

For more information about UCLan's research in this area go to <http://www.uclan.ac.uk/researchgroups/> and search for <name of research Group>.

For information about Research generally at UCLan please go to <http://www.uclan.ac.uk/research/>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <http://clock.uclan.ac.uk/policies/>

1 **Corresponding Author:**

2 Dr Brian W Johnston

3 c/o Royal Liverpool and Broadgreen University Hospital, Prescott Street, Liverpool, L78X

4 brian.johnston@liverpool.ac.uk

5
6
7
8 **Title:**

9
10
11 **Heart rate variability: measurement and emerging use in critical care medicine.**

12
13
14
15 **Authors:**

- 16
17 1) **Dr Brian W Johnston**, University of Liverpool and The Royal Liverpool and Broadgreen
18 University Hospitals, members of Liverpool Health Partners
19 2) **Dr Richard Barrett-Jolley**, University of Liverpool and The Royal Liverpool and
20 Broadgreen University Hospitals, members of Liverpool Health Partners
21 3) **Professor Anton Krige**, University of Central Lancashire
22 4) **Professor Ingeborg D Welters**, University of Liverpool and The Royal Liverpool and
23 Broadgreen University Hospitals, members of Liverpool Health Partners
24

25
26
27
28 **Disclaimers or statement of conflict of interest:**

29
30 No authors have any disclaimers or conflicts of interest to disclose

31
32 **Any financial support received should be acknowledged:**

33
34 No financial support was received for this manuscript
35
36
37

38 **Keywords:**

39
40 Heart rate variability, Autonomic nervous system, Critical care medicine,
41 Electrocardiography, Physiology, Variability analysis
42

Heart rate variability: measurement and emerging use in critical care medicine

Introduction

Stephen Hales in 1733 was the first to report that the time interval between individual arterial pulsations varied in horses.¹ Since then, the introduction of ambulatory ECG has led to the recognition that the time period between successive R waves on the ECG varies in mammals.^{1, 2} This variability between heartbeats or R-R interval (RRi) is a feature of the healthy cardiovascular system and is more commonly known as the heart rate variability (HRV).^{2,3}

Hon and Lee first recognised the clinical potential of HRV when they noted that acute alterations in the HRV were a marker of foetal distress and predicted foetal hypoxia.⁴ Today, monitoring the variability of foetal heart rate has become a standard of care and has been responsible for significant reductions in foetal morbidity and mortality.^{5,4} Similar alterations in HRV have been recognised post myocardial infarction and are associated with a 5-fold increase in mortality.^{6,7} More recently, reduced HRV parameters have been reported as an independent predictor of 30-day mortality and provided additional predictive value over APACHE II scores in critically unwell patients.⁸

The increased appreciation of the clinical potential of HRV analysis has led to its use in various clinical situations common to intensive care medicine including multiorgan dysfunction syndrome (MODS), sepsis and trauma.^{9,10,11} With this in mind, the following review aims to discuss the physiological basis of HRV, the measurement of HRV and the emerging clinical role of HRV analysis in intensive care medicine.

Physiological basis of HRV

Automaticity is common to cardiac pacemaker tissue however, heart rate and rhythm is continuously altered and regulated by the autonomic nervous system (ANS).^{12,2}

The parasympathetic nervous system (PNS) innervates the sinoatrial node, the atrioventricular node, and the atrial myocardium via the vagus nerve.^{13,1} Parasympathetic activation leads to release of acetylcholine (ACh) which slows the heart rate and lengthens the R-R interval.^{1,13} Parasympathetic activation leads to an almost immediate reduction in heart rate due to the very short latency of effect of ACh and the rate at which ACh is rapidly metabolised and cleared.^{1,2} Therefore the PNS regulates heart rate on a near beat by beat basis.¹ In contrast, sympathetic nervous system (SNS) activation initiates the synaptic release of catecholamines, that increase cardiac contractility and heart rate.^{1,2} The action of catecholamines is slow compared to that of ACh and results in a delay between the onset of sympathetic stimulation and changes in heart rate of approximately 5 seconds.^{1,14} Despite the slower onset, sympathetic stimulation has a longer duration of action; affecting heart rate for 5-10 seconds following the cessation of a sympathetic stimulus.^{1,14} The differences in neurotransmitters between the PNS and SNS has led to the recognition that the effects of each arm of the ANS are not opposite and symmetrical but confer overlapping and different time frequencies of action.¹

90 In healthy individuals' cyclical changes in HRV occur with respiration and fluctuations in
91 blood pressure.^{15,16} Frequency domain and power spectral density (PSD) analysis utilizes
92 fast Fourier transform (FFT) analysis to describe oscillations in the RRi and transform them
93 into discrete frequencies that help to conceptualise our understanding of the physiological
94 mechanisms responsible for HRV.^{17,18}

95

96 Since cyclical changes in HRV are associated with respiration and occur at a high frequency
97 (HF) of 0.25Hz they are thought to dominate a number of cardiorespiratory and neural
98 interactions.^{16,2} These interactions are responsible for the observation of respiratory sinus
99 arrhythmia (RSA), characterised by shortening of the RRi with inspiration and lengthening
100 with expiration.¹ Abolition of these high frequency oscillations can be achieved by
101 parasympathetic blockade with atropine suggesting that they are parasympathetically
102 mediated.¹⁵

103

104 Cyclical changes associated with fluctuations in arterial blood pressure (ABP) occur at a low
105 frequency (LF) of 0.10Hz and are thought to be mediated by the SNS.² These oscillations
106 occur in synchrony with arterial Mayer waves.¹ Mayer waves are spontaneous oscillations in
107 ABP whose amplitude is thought to measure sympathetic vasomotor tone.¹⁶ Mayer wave
108 oscillations are thought to parallel oscillations in HRV and in particular the LF oscillations
109 recognised in HRV.¹ These are attenuated and completely abolished by alpha adrenergic
110 antagonist drugs suggesting that sympathetic activity is important in the generation of these
111 oscillations.¹ There remains debate as to the precise physiological origin of Mayer waves in
112 the generation of heart rate frequencies at 0.10Hz and controversy exists in attributing all LF
113 HRV oscillations to sympathetic modulation.¹⁹ Research has demonstrated that
114 parasympathetic blockade also produces modulation of low frequency oscillations in HRV.¹
115 Despite this, measurement of HF and LF oscillations calculated as a ratio of LF/HF has been
116 suggested as a measure of sympathovagal balance with relative changes in the magnitude
117 of each frequency reflecting the dominance of a particular arm of the ANS.^{2,15}

118

119 HF and LF components of HRV account for only 5% of the total power of HRV recordings
120 measured by power spectral density analysis. The remaining 95% is accounted for by two
121 other frequencies called the very-low frequency (VLF) band and ultra-low frequency (ULF)
122 band.¹³ Historically these frequency components have not been well characterised.
123 However, recent research suggests that the VLF band is associated with thermoregulatory
124 mechanisms, changes in peripheral chemoreceptor activity and fluctuations in the renin-
125 angiotensin system (RAAS) whilst the ULF band is thought to reflect oscillations due to
126 circadian rhythm.^{20,17} Despite relatively less being known about the VLF and ULF
127 frequencies, they appear to be clinically important as reduced variability in the VLF band is
128 associated with arrhythmias, high inflammation levels and increased mortality.²¹

129

130 **Measuring Heart Rate Variability**

131

132 In 1996 The European Society of Cardiology and the North American Society of Pacing and
133 Electrophysiology published guidelines aimed at standardising the terminology and
134 methodology used in the measurement of HRV.¹² These guidelines describe a number of
135 methods for measuring HRV including linear measures such as time domain and frequency
136 domain measures and non-linear measures such as the Poincare plot.¹² Recent advances in

137 biological systems theory, HRV analysis and complexity analysis have resulted in updated
138 guidance for non-linear techniques such as entropy and fractal analysis that focus on
139 similarities in the RRi over a given time period.^{20,22}

140

141 **Time domain measures**

142

143 Time domain measures derive HRV using either statistical or geometric analysis.¹² Statistical
144 analyses (e.g. standard deviation) are applied to the RRi to measure variation over a
145 specified period of time from <1min to 24 hours.^{12, 20} Geometric derivation of HRV requires
146 that a series of RRi are converted into a geometric pattern, such as a sample density
147 distribution of RRi and analysed using statistical methods (Table 1).^{12,23}

148

149 Time domain measures are easy to calculate and simple to derive.^{12,24} However, they are
150 sensitive to artefact particularly **supraventricular and ventricular extrasystolic** beats.²⁴
151 Therefore, ECG recordings need careful pre-processing to ensure removal of **extrasystolic**
152 **beats** and interference. Similarly, they require stationarity in the time series (i.e. the mean
153 heart rate does not change significantly), which is a property not often met in biological
154 systems.²⁴ For these reasons time domain measures cannot discriminate between
155 alterations in SNS or PNS output. Despite this, they can be used to assess overall ANS
156 activity, and provide useful clinical information.^{1,24}

157

158 **Frequency domain measures**

159

160 Frequency domain measures describe variation in the RRi following transformation into
161 different frequency components. Frequency domain measures are derived using FFT
162 analysis to provide information on the frequency components of HRV over a time series
163 (Figure 1).^{2,12,24} In analysis of 2 to 5 minute ECG recordings three characteristic frequencies
164 are recognised, LF, HF and VLF (Table 1).²⁴ In 24 hour recordings the ULF band is recognised
165 with the VLF band.¹² In general, to accurately determine the power of a LF banding a
166 recording greater or equal to approximately 5/f is required. Frequency domain, like time
167 domain analysis, is sensitive to artefact, ectopic beats and require stationarity in the data
168 series.²⁴ Physiological mechanisms such as changes in posture, levels of stress and
169 movement are thought to alter LF and HF readings, therefore, factors that are known to
170 modulate the ANS should be controlled during HRV measurement.^{12, 24, 25}

171

172 **Non-linear measures of HRV**

173

174 Non-linear measures overcome the requirement of stationarity in data unlike the linear
175 measures.^{20,26} They include techniques such as the Poincare plot, detrended fluctuation
176 analysis (DFA) and approximate and sample entropy analysis (ApEN and SampEN).²⁶ Non-
177 linear measures model dynamic systems using variables that cannot be plotted on a straight
178 line.²² Physiological systems are dynamic due to complex interactions between
179 cardiovascular, endocrine and autonomic systems and do not ordinarily display stationarity.
180 Therefore non-linear measures may offer a number of advantages over linear HRV measures
181 when stationarity cannot be guaranteed.²⁶ The non-linear methods implicitly assume that
182 the factors that create HRV occur as oscillatory inputs with associated random variation.²⁷
183 Non-linear methods borrow techniques from fractal mathematics and produce variables

184 that describe the pattern of variability by analysing temporal similarities in the signals.²⁷
185 Typically, parameters are derived that separately describe the scaling of short-term
186 variability (e.g. <10 beats) and longer-term trends. Whilst, as yet, these parameters do not
187 offer a great deal of mechanistic insight, they are robust and can distinguish between
188 patient groups.²

189

190 ***Poincare plot***

191

192 Poincare plots are a graphical representation (scatter plot) of HRV generated by plotting
193 each RRi against the prior RRi (Figure 2).²⁰

194

195 Poincare plots are analysed by fitting an ellipse to the data series. Three non-linear
196 measures are typically derived, SD, SD1 and SD2 (Table 1).²⁰ Total variability (S) in the
197 sample is represented by the entire area of the ellipse.²⁰

198

199 ***Detrended fluctuation analysis***

200

201 DFA correlates the fluctuations between RRi over different time scales and analyses
202 temporal self-similarities in the RRi.²⁷ Short term fluctuations are represented by DFA α 1
203 whilst long-term fluctuations are represented by DFA α 2.²⁰ The calculation of DFA involves
204 several steps and during the calculation, non-stationarity in the signal is addressed by
205 subtraction of extrinsic fluctuations, this has been extensively reviewed elsewhere.²⁸ The
206 primary advantage of DFA is removal of confounding due to non-stationarity during DFA
207 calculation.²⁹ However it requires large data sets and whether it offers further information
208 compared to other techniques requires further investigation.^{28,24}

209

210 ***Entropy***

211

212 Entropy analysis can be applied to a series of RRi and provides a measure of the degree of
213 irregularity or “randomness” within the series²⁴. The technique essentially calculates the
214 probability that any given sequence of intervals within the RRi series will be repeated.²⁷ The
215 more likely to be repeated the lower the calculated entropy. Measures of such entropy
216 include the ApnEN and SampEN respectively. Clinically, lower entropy values correlate to a
217 state of illness^{24,30}. SampEN was introduced to address the sensitivity of ApnEN to sample
218 size and the inaccuracy of ApnEN when the number of data points are low in a time series²⁴.

219

220 **Factors affecting HRV measurement**

221

222 Despite the promising ability of HRV to provide information on biological systems there
223 remains a number of physiological and technical issues that need to be considered when
224 interpreting HRV clinically. The context of HRV recording is crucial, as numerous factors
225 including age (increased age leads to reduced HRV), gender (higher HRV in females), resting
226 heart rate and recent physical activity, are thought to alter HRV.²⁰ Factors such as posture
227 and movement also need to be considered as it has been shown that HRV is markedly
228 altered between standing and supine positioning.¹² HRV is also affected by a number of
229 technical factors such as ECG sampling frequency, length of ECG recording and the presence
230 of artefact or interference.^{12,20} To detect the R wave fiducial point on the ECG a sampling

231 frequency minimum of 500Hz is recommended.¹² However as HRV decreases with illness it
232 may be necessary to sample at a much higher frequency to ensure adequate resolution and
233 accuracy.²⁰ A recent systematic review of HRV use in critical care highlighted that a
234 significant number of studies used sampling frequencies as low as 250Hz and these results
235 should be considered with caution.¹¹ Similarly, the length of recording is crucial and can
236 significantly affect time and frequency domain HRV measures. Recommendations have been
237 made regarding acceptable ECG recording lengths for each HRV measure, however the
238 existing literature often fails to accurately report the duration of ECG recordings used in
239 studies, potentially introducing an element of uncertainty to their results.^{11,12} Artefacts can
240 significantly distort time and frequency domain HRV measures and the bias of a single
241 artefact can distort the entire HRV recording. Manual inspection of ECG is recommended to
242 ensure HRV analysis is conducted on ECG segments that are free of artefact, ectopic beats,
243 missed beats and interference.¹² Artefacts such as missed and ectopic beats can be resolved
244 by artefact removal and interpolation of an R wave based on previous QRS intervals.²⁰
245 However, with increasing interpolation of R waves a significant amount of noise to signal
246 ratio can be introduced in the data series and lead to errors in HRV measures. **Similarly,**
247 **arrhythmias such as atrial fibrillation (AF) can introduce significant distortion in HRV and**
248 **therefore should not be considered accurate in patients with AF.** These factors need to be
249 considered when interpreting HRV in the clinical context.

250

251

252 **HRV in Intensive Care Medicine**

253

254 **HRV is frequently used to describe the activity of the SNS and PNS. However, this relies on**
255 **the assumption that the autonomic nervous system is in balance, with low PNS activity**
256 **associated with a correspondingly high SNS activity and vice versa.³¹ Many authors have**
257 **refuted this, and it is generally accepted that the relative balance of the ANS is more**
258 **complex.**

259

260 **Similarly, mechanisms responsible for RRI and HRV are complex and reflect inputs from**
261 **multiple physiological systems, including the SNS, PNS, renin-angiotensin system,**
262 **thermoregulatory systems, as well as mechanical inputs from respiration and alterations in**
263 **arterial blood pressure.³²**

264

265 **Despite debate regarding the association between HRV and the ANS, the previous two**
266 **decades have witnessed a significant expansion in the use of HRV analysis and increasing**
267 **evidence supporting its use in critical care.¹¹**

268

269 Autonomic dysfunction is common to a number of disorders seen in critical care patients,
270 such as MODS, sepsis, myocardial infarction, decompensated heart failure and severe brain
271 injury (SBI).^{11,33,34} The ability to assess autonomic function may provide valuable
272 information regarding the pathophysiology, severity and prognosis of these disorders.³³
273 **However the reader is reminded that whilst an association between HRV and the ANS**
274 **certainly exists, HRV does not directly measure autonomic activity and any association is**
275 **likely a combination of complex physiological inputs.³¹ With this in mind the remainder of**
276 **this review will focus on areas in which HRV has found utility in intensive care medicine.**

277

278 **Multiple organ dysfunction syndrome and Sepsis**

279

280 As early as 1995 it was recognised that SDNN, LF, LF/HF are reduced in sepsis.^{11,35, 36,37} Godin
281 and Buchman suggested that organ systems are connected to each other via neural,
282 hormonal and cytokine networks and that they each behave as biological oscillators.³⁸ They
283 hypothesised that sepsis resulted in an uncoupling of organ systems and leads to a
284 reduction in HRV parameters.^{38,30} They proposed that HRV was a method for the
285 quantification of 'inter-organ communication' and yielded valuable information in the
286 pathophysiology of sepsis and prognosis of patients admitted to the intensive care unit
287 (ITU).³⁸ Recently, Bishop et al reported that reduction in the VLF domain was predictive of
288 30 day all-cause mortality in patients admitted to ITU.³⁹ Similar findings have been reported
289 by Schmidt who found that a reduced VLF was predictive of 28 day mortality in patients with
290 MODS.⁴⁰ HRV analysis may be able to predict mortality early in a patient's presentation,
291 with Chen reporting that a reduced SDNN was predictive of in-hospital mortality in septic
292 patients admitted to the accident and emergency department.⁹ Interestingly, Chen also
293 reported that an increased HF was predictive of hospital survival, suggesting that health is
294 associated with a high degree of variability.⁹ This was confirmed by Papaioannou in a novel
295 study that tracked changing HRV in response to a patient's pathophysiological state.⁴¹ SOFA
296 scores were longitudinally tracked with a number of HRV measures over time and revealed
297 that entropy was reduced in non-survivors, and the long term non-linear HRV parameter
298 DFA α 2 correlated with length of ITU stay.⁴¹ Moreover, patients that were more clinically
299 unstable had a reduced LF/HF ratio, and a reduction in overall variance.⁴¹ This recovered as
300 patients improved and were finally discharged from critically care, suggesting that HRV
301 analysis may be valuable as a method of monitoring physiological deterioration and offer
302 real time prognostication in critically unwell patients.⁴¹

303

304 HRV may also serve to predict those patients at risk of deterioration and those who may
305 benefit from early ITU admission. In a recent observational study in septic emergency
306 department patients, Samsudin et al report a scoring system utilising two vital signs
307 (respiratory rate and systolic blood pressure), age and two HRV measures (mean RRi and
308 DFA α 2).⁴² They revealed that the use of HRV not only outperformed SOFA, NEWS and
309 MEWS scoring at prediction of 30 day mortality but, was also able to accurately predict
310 those patients requiring ITU admission and intubation.⁴² Similar scoring systems utilising
311 HRV have already shown promise in neonatal patients. In the landmark HeRO Trial,
312 Moorman et al revealed that monitoring heart rate characteristics including reduced
313 variability and transient heart rate decelerations, led to a 22% relative reduction in mortality
314 in very low birthweight neonates.⁴³ The HeRO trial provided clinicians with a score based
315 upon a composite measure utilising SD RRi, sample asymmetry (a measure of transient
316 accelerations and deceleration of the heart rate) and SampEN.⁴⁴ Using multivariable logistic
317 regression and mathematical algorithms, the HeRO score provides continuous non-invasive
318 monitoring that estimates the fold-increase in the probability of sepsis.^{44,43} The HeRO trial
319 and scoring systems developed by Samsudin hint at the possibility of a new generation of
320 physiometers for the earlier detection of deterioration and sepsis.^{42,44}

321

322 **HRV and inflammation**

323

324 Inflammation is associated with a number of conditions that present to ITU such as
325 myocardial infarction, sepsis, systemic inflammatory response syndrome, MODs and severe
326 trauma.⁴⁵ Factors that trigger inflammation also enhance anti-inflammatory pathways that
327 counterbalance the initial pro-inflammatory signal.^{45, 21} An inflammatory reflex has been
328 described in which cytokines induce neuroendocrine modulatory mechanisms that signal via
329 the autonomic nervous system.^{21,45} In response to inflammation vagal outflow increased
330 systemically and more specifically to organs such as the spleen that are thought to be
331 responsible for the upregulation of anti-inflammatory cytokine levels.^{45,46} It is thought that
332 this counter-regulatory mechanism confers protection against unregulated tissue damage in
333 inflammatory conditions and poly-microbial infection and is known as the 'cholinergic anti-
334 inflammatory pathway.'⁴⁵ HRV analysis has helped elucidate the role the ANS plays in the
335 inflammatory reflex, and a depressed parasympathetic activity has been implicated in the
336 pathogenesis of diseases associated with an exaggerated inflammatory response.⁴⁵ A
337 number of authors have correlated HRV with inflammatory markers.^{21,47,48} Tateishi
338 investigated the relationship between IL-6 and HRV in patients admitted to critical care with
339 sepsis and found that IL-6 was negatively correlated with the LF component of HRV
340 analysis.⁴⁷ Papaioannou tracked patients from admission to critical care and reported an
341 inverse correlation between LF and LF/HF and C-reactive protein (CRP) levels.²¹ HF HRV was
342 correlated with IL-10 levels, suggesting that LF/HF ratio and reduced LF HRV is related to
343 both pro-inflammatory and anti-inflammatory responses.²¹ Furthermore, those patients
344 that developed shock had increased biomarkers (CRP, IL-6, IL-10) and decreased HRV,
345 reaching statistical significance in patients with a SOFA score >10.²¹ This suggests that HRV is
346 related to both anti-inflammatory and pro-inflammatory signals with a stronger association
347 being present in patients that are more unwell.²¹

348

349 There is strong evidence that the ANS influences the physiological response to inflammation
350 and recent research suggests that the anticholinergic anti-inflammatory pathway may hold
351 promise as a therapeutic target.^{21,49} HRV measurement may therefore prove to be a novel
352 physiomeasure that characterises the cardiorespiratory responses to inflammation and may
353 have prognostic value in any future anti-inflammatory treatments.⁵⁰

354

355 **Cardiovascular disorders, arrhythmias and cardiac arrest**

356

357 It is generally accepted that HRV is a powerful predictor of cardiac mortality, arrhythmia and
358 sudden cardiac death, and is independent of other risk factors (left ventricular ejection
359 fraction, ventricular extra-systoles and episodes of non-sustained ventricular tachycardia)
360 after myocardial infarction.^{5,7,12,51} A substudy of the large ATRAMI trial found that
361 decreased SDNN and impaired heart rate response to an increase in blood pressure
362 (baroreceptor sensitivity) were predictors of cardiac mortality.⁵² In patients with a reduced
363 ejection fraction, the presence of a reduced SDNN or low baroreceptor sensitivity carried a
364 relative risk of mortality of 6.7 and 8.7 respectively.⁵² Reduced HRV may also provide an
365 early warning of deterioration as Passariello et al has shown that patients who suffer
366 sudden cardiac death secondary to fatal arrhythmia have a marked decrease in SDNN in the
367 five minutes preceding its onset.⁵³ Similar findings are reported in patients that suffer from
368 paroxysmal AF, where ApnEN was decreased up to 100 minutes prior to the onset of
369 arrhythmia.²² That HRV analysis appears to be able to predict patients at risk of cardiac

370 mortality and arrhythmias may prove useful for risk stratification, particularly in patients at
371 increased cardiovascular risk such as in the peri-operative period.³³

372

373 HRV has also been used to monitor the responses to drug treatment in patients with
374 cardiovascular disease and hypertension. Beta-antagonists such as metoprolol and atenolol
375 tend to augment HF whilst reducing LF in patients with hypertension.⁵⁴ Similar findings have
376 been reported post myocardial infarction, where the addition of metoprolol led to a
377 reduction in LF output.⁵⁴ However, cardiovascular drugs such as, statins and calcium channel
378 antagonists have been found to have a variable effect on HRV.¹¹ Interestingly drugs that
379 would be expected to have profound effects on the ANS such as catecholamines have also
380 been shown to have variable effects on HRV. A recent systematic review reported three
381 studies that did not show any association between HRV parameters and vasopressor
382 requirement or administration of exogenous catecholamines.¹¹ Despite no finding of an
383 association the authors highlighted that the majority of studies failed to report the
384 administration of cardiovascular drugs, vasopressors or catecholamines and had limited
385 ability to draw any conclusions regarding the potential effects on HRV.^{11,54}

386

387 HRV may also offer important information regarding neurological recovery post cardiac
388 arrest.^{33,55} Tiainen et al in a randomised trial reported significantly higher HRV measures in
389 those patients that underwent therapeutic hypothermia (TH) compared to normothermia
390 post cardiac arrest.⁵⁵ Higher SDNN, SDANN, HF and LF measures were recorded in the first
391 48 hours of TH.⁵⁵ The authors suggest that higher HRV measures may represent a beneficial
392 effect on myocardial function and preservation of ANS function or the neuroprotective
393 effects of cooling.⁵⁵ However, they acknowledge that this finding may be due to
394 confounding and secondary to the relative bradycardia that TH induces in patients.⁵⁵ The
395 exact mechanism underlying improved HRV with TH remains uncertain, despite this the
396 potential of HRV to predict outcome post cardiac arrest should be confirmed with larger
397 trials.^{33,55}

398

399 **Neurological disorders**

400

401 Lowhenshon was amongst the first authors to investigate the links between HRV and
402 neurological disorders.⁵⁶ In brain-damaged adults Lowhenshon revealed that HRV decreased
403 and rapidly diminished in line with increases in intracranial pressure (ICP).⁵⁶ A more recent
404 study in 145 trauma patients confirmed that an increase in intracranial pressure, as
405 measured by invasive intracranial pressure monitoring, is preceded by a reduction in heart
406 rate variability.⁵⁷ Reduction in HRV has been shown to be proportional to the increase in
407 intracranial pressure, with more marked alterations in HRV occurring when ICP was
408 >30mmHg or cerebral perfusion pressure <40mmHg.³³ Moreover, reductions in HRV
409 preceded changes in ICP by approximately 24 hours.⁵⁷ These findings suggest that HRV may
410 function as a non-invasive method of monitoring early changes in intracranial pressure and
411 may identify those patients that would benefit from invasive monitoring.⁵⁷

412

413 Complications following subarachnoid haemorrhage (SAH) can include severe vasospasm,
414 neurogenic stress cardiomyopathy, and cardiac arrhythmias.⁵⁸ Reduction in RMSSD has
415 been shown to be associated with neurogenic stress cardiomyopathy following SAH.⁵⁸
416 Similar alterations in HRV have been recognised in extradural, subdural, and intracerebral

417 haematomas.³³ Schmidt et al have investigated VLF reductions and delayed cerebral
418 ischaemia secondary to cerebral vasospasm in SAH patients.⁵⁹ It is thought that VLF may
419 partly represent parasympathetic outflow and reductions in VLF are associated with states
420 of high inflammation.²⁰ Both RMSSD and VLF have been shown to predict complications
421 following SAH, and it has been suggested that this may be related to the pro-inflammatory
422 response contributing to the development of cerebral ischaemia after SAH.⁵⁹

423
424 Changes in HRV have also been shown to be an early indication of the occurrence of brain
425 death.⁶⁰ Conci reported a reduction in the total power of frequency domain analysis and
426 suggested that these changes likely mirror a cessation of the activity of cardiorespiratory
427 brainstem centres.⁶⁰ These findings have been confirmed by others who measured
428 continuous HRV and found that the loss of spectral power occurred during the transition to
429 brain death.⁶¹ Taken together these findings may be useful as a complementary method in
430 the diagnosis of brain stem death and help inform when more formal brain stem death
431 testing should occur.^{60,61}

432

433

434 **Conclusion**

435

436 HRV analysis offers a unique monitoring modality that provides information regarding
437 variability in complex biological signals. Unlike existing monitoring, HRV can potentially
438 detect and track the state of the whole physiological system over time and during the
439 development of illness, potentially even before it is clinically apparent. Goldberger
440 described illness as the de-complexification of complex biological systems and suggested
441 that health is characterised by 'organised variability' whilst reduced variability is associated
442 with disease states, such as multi-organ dysfunction syndrome and sepsis.⁶² The inclusion of
443 HRV measures into current early warning scoring systems such as NEWS could potentially
444 lead to a new generation of physiomarkers that can predict deterioration earlier and help
445 target those patients at greatest risk of mortality.⁴² The HeRO trial and HeRO monitoring
446 system has shown that incorporation of HRV measures can potentially lead to earlier
447 investigation and treatment and significantly improved clinical outcomes.⁴⁴

448

449 **Despite the potential of HRV measurement, it is still largely a research technique and has**
450 **not become part of routine monitoring in critical care.⁶³ There are a number of potential**
451 **reasons for this. First, despite the large number of experimental studies, the majority are**
452 **cohort or case-control studies of low methodological quality.¹¹ Many studies also failed to**
453 **fully account for confounding factors such as commonly used drugs in ITU including anti-**
454 **arrhythmic medications and the impact that interventions in ITU such as mechanical**
455 **ventilation have on HRV parameters.¹¹ Second, there is a lack of standardised methodology**
456 **for the recording, processing and derivation of HRV from ECG. Despite guidelines from The**
457 **European Society of Cardiology and the North American Society of Pacing and**
458 **Electrophysiology, obtaining clinically useful HRV parameters still requires clinicians to pre-**
459 **process ECG and RRi data using standard ECG monitoring equipment before using**
460 **standalone software to derive HRV parameters.¹² A number of open source software**
461 **packages written in Matlab mathematical language are available as well as a number of paid**
462 **software packages such as Kubios and ARTiiFACT.^{64,65,66} To date the authors are not aware**
463 **of any monitoring systems that derive HRV in real-time at the bedside and this likely limits**

464 its widespread use in ITU. Third, despite evidence to suggest that HRV can predict
465 deterioration, arrhythmias and MODS, the exact pathophysiological mechanisms underlying
466 these associations remains unclear. Throughout this review we have discussed HRV as a
467 measure of autonomic function. In reality individual HRV parameters are more complex and
468 multiple physiological factors impact upon them.³¹ Until the exact mechanisms responsible
469 for measured HRV parameters are uncovered it is difficult to fully define a mechanistic basis
470 for HRV.³¹

471

472 Measurement of HRV, along with advances in biomedical engineering and computational
473 methods, has increased our understanding of the role the ANS plays in the pathophysiology
474 of disease and illness. But for HRV analysis to become a standard of monitoring in critical
475 care, prospective studies are needed to address the technical considerations, determine
476 what factors confound HRV analysis, and develop consensus standards for HRV monitoring
477 in critical care. In conclusion if these challenges are addressed, HRV analysis has the
478 potential to revolutionise critical care monitoring and introduce an era of monitoring based
479 upon individualised variability analysis.

480

481 **References**

482

- 483 1. Draghici, A. E. & Taylor, J. A. The physiological basis and measurement of heart rate
484 variability in humans. *J. Physiol. Anthropol* 2016; 35: 22.
- 485 2. Pumprla, J., Howorka, K., Groves, D., Chester, M. & Nolan, J. Functional assessment of
486 heart rate variability: physiological basis and practical applications. *Int. J. Cardiol*
487 2002;84: 1–14.
- 488 3. Lombardi, F. & Stein, P. K. Origin of heart rate variability and turbulence: An appraisal
489 of autonomic modulation of cardiovascular function. *Front. Physiol* 2011; 2 :1–7.
- 490 4. Hon, E. H. & Lee, S. T. Electronic Evaluation of the Fetal Heart Rate. Viii. Patterns
491 Preceding Fetal Death, Further Observations. *Am. J. Obstet. Gynecol* 1963; 87 814–
492 26.
- 493 5. Billman, G. E. Heart rate variability - a historical perspective. *Front. Physiol* 2011; 2:
494 86.
- 495 6. Wolf, M. M., Varigos, G. A., Hunt, D. & Sloman, J. G. Sinus arrhythmia in acute
496 myocardial infarction. *Med. J. Aust* 1978; 2: 52–3.
- 497 7. Kleiger, R. E., Miller, J. P., Bigger, J. T. & Moss, A. J. Decreased Heart Rate Variability
498 and Its Association with Increased Mortality After Acute Myocardial Infarction. *Am J*
499 *Cardiol* 1987; 59: 258–282.
- 500 8. Bishop, D. G., Wise, R. D., Lee, C. & Rahden, R. P. Von. Heart rate variability predicts
501 30-day all-cause mortality in intensive care units. *Southern African Journal of*
502 *Anaesthesia and Analgesia* 2016; 22: 125–128.
- 503 9. Chen WL, Chen JH, Huang CC, Kuo CD, Huang CI, Lee LS. Heart rate variability
504 measures as predictors of in-hospital mortality in ED patients with sepsis. *Am. J.*
505 *Emerg. Med* 2008; 26: 395–401.
- 506 10. Ahmad S¹, Ramsay T, Huebsch L, Flanagan S, McDiarmid S, Batkin I, McIntyre
507 L, Sundaresan SR, Maziak DE, Shamji FM, Hebert P, Fergusson D, Tinmouth A, Seely
508 AJ. Continuous Multi-Parameter Heart Rate Variability Analysis Heralds Onset of
509 Sepsis in Adults. *PLoS One* 2009; 4 (8):e6642.
- 510 11. Karmali, S. N., Sciusco, A., May, S. M. & Ackland, G. L. Heart rate variability in critical
511 care medicine: a systematic review. *Intensive Care Med. Exp.* 2017; 5: 33.
- 512 12. Heart rate variability Standards of measurement, physiological interpretation, and
513 clinical use. *Eur. Heart J.* 1996; **17**: 354–381.
- 514 13. Shaffer, F., McCraty, R. & Zerr, C. L. A healthy heart is not a metronome: an
515 integrative review of the heart’s anatomy and heart rate variability. *Front. Psychol.*
516 2014; 5: 1–19.
- 517 14. Hainsworth, R, Malik, M, Camm, A. (1995) The control and physiological importance
518 of heart rate: Heart Rate Variability. Futura Publishing Company.
- 519 15. Keselbrener, L. & Akselrod, S. (1998) Autonomic Responses to Blockades and
520 Provocations. In: Malik M. (eds) *Clinical Guide to Cardiac Autonomic Tests* p101–148
521 Springer Netherlands.
- 522 16. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone
523 G, Malfatto G, Dell’Orto S, Piccaluga E. Power spectral analysis of heart rate and
524 arterial pressure variabilities as a marker of sympatho-vagal interaction in man and
525 conscious dog *Circ. Res.* 1986; 59: 178–93.
- 526 17. Akselrod S, Gordon D, Ubel FA, Shannon DC, Berger AC, Cohen RJ.. Power Spectrum
527 Analysis of Heart Rate Fluctuation: A Quantitative. *Science* 1981; 213: 220–222.

- 528 18. Perini R, Veicsteinas A. Heart rate variability and autonomic activity at rest and during
529 exercise in various physiological conditions. *Eur J Appl Physiol.* 2003; 90(3-4): 317-25.
- 530 19. Julien, C. The enigma of Mayer waves: Facts and models. *Cardiovasc Res.* 2006; 70(1):
531 12-21.
- 532 20. Shaffer, F. & Ginsberg, J. P. An Overview of Heart Rate Variability Metrics and Norms.
533 *Front. Public Heal.* 2017; 5: 1–17.
- 534 21. Papaioannou, V. E., Dragoumanis, C., Theodorou, V., Gargaretas, C. & Pneumatikos, I.
535 Relation of heart rate variability to serum levels of C-reactive protein, interleukin 6,
536 and 10 in patients with sepsis and septic shock. *J. Crit. Care* 2009; 24: 625.e1-625.e7.
- 537 22. Sassi, R. *et al.* Advances in heart rate variability signal analysis: joint position
538 statement by the e-Cardiology ESC Working Group and the European Heart Rhythm
539 Association co-endorsed by the Asia Pacific Heart Rhythm Society. *Europace* 2015; 17:
540 1341–1353.
- 541 23. Hnatkova, K., Copie, X., Staunton, A. & Malik, M. Numeric processing of Lorenz plots
542 of R-R intervals from long-term ECGs. Comparison with time-domain measures of
543 heart rate variability for risk stratification after myocardial infarction. *J. Electrocardiol*
544 1995; 28: 74–80.
- 545 24. Seely, A. J. E. & Macklem, P. T. Complex systems and the technology of variability
546 analysis. *Crit. Care* 2004; 8: R367-84.
- 547 25. Merri, M., Farden, D. C., Mottley, J. G. & Titlebaum, E. L. Sampling frequency of the
548 electrocardiogram for spectral analysis of the heart rate variability. *IEEE Trans.*
549 *Biomed. Eng.* 1990; 37: 99–106.
- 550 26. Buccelletti F, Bocci MG, Gilardi E, Fiore V, Calcinaro S, Fragnoli C, Maviglia
551 R, and Franceschi F. Linear and nonlinear heart rate variability indexes in clinical
552 practice. *Comput. Math. Methods Med.* 2012.
- 553 27. Ernst, G. Hidden Signals-The History and Methods of Heart Rate Variability. *Front.*
554 *public Heal.* 2017; 5 265.
- 555 28. Peng, CK, Havlin S., Stanley, HE & Goldberger AL. Quantification of scaling exponents
556 and crossover phenomena in nonstationary heartbeat time series. *Chaos An*
557 *Interdiscip. J. Nonlinear Sci.* 1995; 5: 82–87.
- 558 29. Goldberger, A. L. et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a
559 new research resource for complex physiologic signals. *Circulation* 2002; 101: E215-
560 20.
- 561 30. Pincus, S. M. Assessing serial irregularity and its implications for health. *Ann. N. Y.*
562 *Acad. Sci.* 2001; 954: 245–67.
- 563 31. Ernst, G. Heart-Rate Variability—More than Heart Beats? *Front. Public Heal.* 2017; 5:
564 1–12.
- 565 32. Fleisher, L. Heart rate variability as an assessment of cardiovascular status. *J.*
566 *Cardiothorac. Vasc. Anesth.* 1996 10, 659–671.
- 567 33. Mazzeo, A. T., La Monaca, E., Di Leo, R., Vita, G. & Santamaria, L. B. Heart rate
568 variability: A diagnostic and prognostic tool in anesthesia and intensive care. *Acta*
569 *Anaesthesiol. Scand.* 2011; 55: 797–811.
- 570 34. Shaffer, F. et al. Association of heart rate variability and inflammatory response in
571 patients with cardiovascular diseases: Current strengths and limitations. *Front.*
572 *Physiol.* 2013; 5: 1–13.
- 573 35. Annane, D. et al. Inappropriate Sympathetic Activation at Onset of Septic Shock A
574 Spectral Analysis Approach. *Am J Respir Crit Care Med* 1999; 160: 458–465.

- 575 36. Buchan, C. A., Bravi, A. & Seely, A. J. E. Variability Analysis and the Diagnosis,
576 Management, and Treatment of Sepsis. *Curr. Infect. Dis. Rep.* 2012; 14: 512–521.
- 577 37. Piepoli, M., Garrard, C. S., Kontoyannis, D. A. & Bernardi, L. Autonomic control of the
578 heart and peripheral vessels in human septic shock. *Intensive Care Med.* 1995; 21:
579 112–9.
- 580 38. Godin, P. J. & Buchman, T. G. Uncoupling of biological oscillators: a complementary
581 hypothesis concerning the pathogenesis of multiple organ dysfunction syndrome.
582 *Crit. Care Med.* 1996; 24: 1107–16.
- 583 39. Bishop, D. G., Wise, R. D., Lee, C., Von Rahden Ab, R. P. & Rodseth, R. N. South Afr J
584 Anaesth Analg Heart rate variability predicts 30-day all-cause mortality in intensive
585 care units. *South. African J. Anaesth. Analg.* 2016; 22: 125–128.
- 586 40. Schmidt H, Hoyer D, Hennen R, Heinroth K, Rauchhaus M, Prondzinsky R, Hottenrott
587 K, Buerke M, Müller-Werdan U, Werdan K.. Autonomic dysfunction predicts both 1-
588 and 2-month mortality in middle-aged patients with multiple organ dysfunction
589 syndrome. *Crit. Care Med.* 2008; 36: 967–970.
- 590 41. Papaioannou, V. E., Maglaveras, N., Houvarda, I., Antoniadou, E. & Vretzakis, G.
591 Investigation of altered heart rate variability, nonlinear properties of heart rate
592 signals, and organ dysfunction longitudinally over time in intensive care unit patients.
593 *J. Crit. Care* 2006; 21: 95–103.
- 594 42. Samsudin MI, Liu N, Prabhakar SM, Chong SL, Kit Lye W, Koh ZX, Guo D, Rajesh R, Ho
595 AFW, Ong MEH. A novel heart rate variability based risk prediction model for septic
596 patients presenting to the emergency department. *Medicine.* 2018; 97: e10866.
- 597 43. Moorman JR, Carlo WA, Kattwinkel J, Schelonka RL, Porcelli PJ, Navarrete
598 CT, Bancalari E, Aschner JL, Whit Walker M, Perez JA, Palmer C, Stukenborg GJ, Lake
599 DE, Michael O'Shea T. Mortality reduction by heart rate characteristic monitoring in
600 very low birth weight neonates: a randomized trial. 2011; 159(6):900-6.e1
- 601 44. Fairchild KD, Schelonka RL, Kaufman DA, Carlo WA, Kattwinkel J, Porcelli PJ, Navarrete
602 CT, Bancalari E, Aschner JL, Walker MW, Perez JA, Palmer C, Lake DE, O'Shea
603 TM, Moorman JR. Septicemia mortality reduction in neonates in a heart rate
604 characteristics monitoring trial. *Pediatr Res.* 2013;74(5): 570-5.
- 605 45. Huston, J. M. & Tracey, K. J. The Pulse of Inflammation: Heart Rate Variability, the
606 Cholinergic Anti-Inflammatory Pathway, and Implications for Therapy. *J Intern Med.*
607 2011; 269(1): 45–53.
- 608 46. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang
609 H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic
610 inflammatory response to endotoxin. *Nature* 2000; 405: 458–462.
- 611 47. Tateishi Y¹, Oda S, Nakamura M, Watanabe K, Kuwaki T, Moriguchi T, Hirasawa H.
612 Depressed Heart Rate Variability Is Associated With High Il-6 Blood Level And Decline
613 In The Blood Pressure In Septic Patients. *Shock* 2007;28: 549–553.
- 614 48. Jan BU¹, Coyle SM, Macor MA, Reddell M, Calvano SE, Lowry SF.
615 Relationship of Basal Heart Rate Variability to In Vivo Cytokine Responses after
616 endotoxin exposure. *Shock* 2010; 33: 363–368.
- 617 49. Kanashiro A, Sônego F, Ferreira RG, Castanheira FV, Leite CA, Borges VF, Nascimento
618 DC, Cólón DF, Alves-Filho JC, Ulloa L, Cunha FQ. Therapeutic potential and limitations
619 of cholinergic anti-inflammatory pathway in sepsis. *Pharmacol. Res.* 2017; 117: 1–8.
- 620 50. Pontet J, Contreras P, Curbelo A, Medina J, Noveri S, Bentancourt S, Migliaro ER.
621 Heart rate variability as early marker of multiple organ dysfunction syndrome in

- 622 septic patients. *J. Crit. Care* 2003; 18: 156–163.
- 623 51. Billman, G. E., Huikuri, H. V., Sacha, J. & Trimmel, K. An introduction to heart rate
624 variability: methodological considerations and clinical applications. *Front. Physiol.*
625 2015 ; 6: 55.
- 626 52. La Rovere, M. T., Bigger, J. T., Marcus, F. I., Mortara, A. & Schwartz, P. J. Baroreflex
627 sensitivity and heart-rate variability in prediction of total cardiac mortality after
628 myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial
629 Infarction) Investigators. *Lancet* 1998; 351: 478–84.
- 630 53. Passariello G, Peluso A, Moniello G, Maio A, Mazo S, Boccia G, Passariello N, Lettieri
631 B, Chiefari M. Effect of autonomic nervous system dysfunction on sudden death in
632 ischemic patients with anginal syndrome died during electrocardiographic monitoring
633 in Intensive Care Unit. *Minerva Anesthesiol.* 2007; 73: 207–12 (2007).
- 634 54. Rajendra Acharya U, Paul Joseph K, Kannathal N, Lim CM, Suri JS. Heart rate
635 variability: A review. *Med. Biol. Eng. Comput.* 2006; 44: 1031–1051.
- 636 55. Tiainen M, Parikka HJ, Mäkijärvi MA, Takkunen OS, Sarna SJ, Roine RO.. Arrhythmias
637 and heart rate variability during and after therapeutic hypothermia for cardiac arrest.
638 *Crit. Care Med.* 2009; 37: 403–409.
- 639 56. Lowensohn, R. I., Weiss, M. & Hon, E. H. Heart-rate variability in brain-damaged
640 adults. *Lancet* 1977; 1: 626–8.
- 641 57. Mowery NT, Norris PR, Riordan W, Jenkins JM, Williams AE, Morris JA. Cardiac
642 Uncoupling and Heart Rate Variability are Associated With Intracranial Hypertension
643 and Mortality: A Study of 145 Trauma Patients With Continuous Monitoring. *J.*
644 *Trauma Inj. Infect. Crit. Care* 2008; 65: 621–627.
- 645 58. Park, S., Kaffashi, F., Loparo, K. A. & Jacono, F. J. The use of heart rate variability for
646 the early detection of treatable complications after aneurysmal subarachnoid
647 hemorrhage. *J Clin Monit Comput.* 2013; 27(4): 385-93
- 648 59. Schmidt JM, Sow D, Crimmins M, Albers D, Agarwal S, Claassen J, Connolly ES, Elkind
649 MS, Hripcsak G, Mayer SA. Heart Rate Variability for Preclinical Detection of
650 Secondary Complications after Subarachnoid Hemorrhage. *Neurocrit Care.* 2014;
651 20(3): 382-9
- 652 60. Conci, F., Rienzo, D. & Castiglioni, P. Blood pressure and heart rate variability and
653 baroreflex sensitivity before and after brain death. *J Neurol Neurosurg Psychiatry*
654 2001; 71: 621–631.
- 655 61. Baillard C, Vivien B, Mansier P, Mangin L, Jasson S, Riou B, Swynghedauw B.. Brain
656 death assessment using instant spectral analysis of heart rate variability. *Crit. Care*
657 *Med.* 2002; 30: 306–10.
- 658 62. H. E. Stanley, L. A N Amaral, A. L. Goldberger, S. Havlin, P. Ch Ivanov, C. K.
659 Peng Statistical physics and physiology: Monofractal and multifractal approaches.
660 *Phys. A Stat. Mech. its Appl.* 1999; 270: 309–324.
- 661 63. Sztajzel, J. Heart rate variability: A noninvasive electrocardiographic method to
662 measure the autonomic nervous system. *Swiss Med. Wkly* 2004; 134: 514–522.
- 663 64. Niskanen, J.-P., Tarvainen, M. P., Ranta-aho, P. O. & Karjalainen, P. A. Software for
664 advanced HRV analysis. *Comput. Methods Programs Biomed.* 2004; 76: 73–81.
- 665 65. Tarvainen, M. P., Niskanen, J.-P., Lipponen, J. A., Ranta-aho, P. O. & Karjalainen, P. A.
666 Kubios HRV – Heart rate variability analysis software. *Comput. Methods Programs*
667 *Biomed.* 2014; 113: 210–220.
- 668 66. Kaufmann, T., Sütterlin, S., Schulz, S. M. & Vögele, C. ARTiiFACT: a tool for heart rate

669 artifact processing and heart rate variability analysis. Behav. Res. Methods 2011; 43,
670 1161–1170.
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702

